EFFECT OF CAFFEIC ACID PHENETHYL ESTER ON DOXORUBICIN-INDUCED HYPERINFLAMMATION IN PRECLINICAL MODELS OF TRIPLE-NEGATIVE BREAST CANCER

被引：0
|
作者：
Fosu, Kwadwo [1 ]
Aikins, Anastasia Rosebud [1 ]
Sarpong, Kwabena [1 ]
机构：
[1] Univ Ghana, Mol Biol, Accra, Ghana
来源：
ONCOLOGY NURSING FORUM | 2023年 / 50卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P404
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Caffeic acid phenethyl ester counteracts doxorubicin-induced chemobrain in Sprague-Dawley rats: Emphasis on the modulation of oxidative stress and neuroinflammation
    Ali, Marwa A.
    Menze, Esther T.
    Tadros, Marianne G.
    Tolba, Mai F.
    NEUROPHARMACOLOGY, 2020, 181
  • [22] Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer
    Woo, Sang-Mi
    Kim, Ah Jeong
    Choi, Youn Kyung
    Shin, Young Cheol
    Seong-, Sung-Gook Cho
    Ko, Seong-Gyu
    PHYTOTHERAPY RESEARCH, 2016, 30 (11) : 1817 - 1823
  • [23] Preclinical analyses of synergistic effect of eribulin and paclitaxel for triple-negative breast cancer
    Oba, Takaaki
    Ito, Ken-ichi
    CANCER RESEARCH, 2017, 77
  • [24] The effect of caffeic acid phenethyl ester on cell cycle control gene expressions in breast cancer cells
    Balc-Okcanoglu, Tugce
    Yilma-Susluer, Sunde
    Kayabasi, Cagla
    Ozme-Yelken, Besra
    Biray-Avci, Cigir
    Gunduz, Cumhur
    MOLECULAR BIOLOGY RESEARCH COMMUNICATIONS, 2021, 10 (01) : 39 - 43
  • [25] Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
    Kurt Schönfeld
    Peter Herbener
    Chantal Zuber
    Thomas Häder
    Katrin Bernöster
    Christoph Uherek
    Jörg Schüttrumpf
    Pharmaceutical Research, 2018, 35
  • [26] Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models
    Schoenfeld, Kurt
    Herbener, Peter
    Zuber, Chantal
    Haeder, Thomas
    Bernoester, Katrin
    Uherek, Christoph
    Schuettrumpf, Joerg
    PHARMACEUTICAL RESEARCH, 2018, 35 (06)
  • [27] Carfilzomib demonstrates antiproliferative and proapoptotic activities in preclinical triple-negative breast cancer models
    Larson, Mathew
    Carlson, Jennifer H.
    Sun, Yuliang
    Bucholz, Tonia
    Williams, Casey
    Dey, Nandini
    Leyland-Jones, Brian
    De, Pradip
    CANCER RESEARCH, 2016, 76
  • [28] Targeting the gp130 receptor in preclinical models of triple-negative breast cancer
    Hernandez-Aya, Leonel F.
    Liu, Yajing
    Kerr, Kelsey
    Tamura, Shuzo
    Neamati, Noun
    Wicha, Max S.
    Burness, Monika L.
    CANCER RESEARCH, 2015, 75
  • [29] Preclinical studies with neratinib in triple-negative breast cancer.
    Mulloly, Maeve
    O'Brien, Neil A.
    Conklin, Dylan
    Finn, Richard S.
    Slamon, Dennis J.
    Crown, John
    O'Donovan, Norma
    McGowan, Patricia M.
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
    Giro-Perafita, Ariadna
    Palomeras, Sonia
    Lum, David H.
    Blancafort, Adriana
    Vinas, Gemma
    Oliveras, Gloria
    Perez-Bueno, Ferran
    Sarrats, Ariadna
    Welm, Alana L.
    Puig, Teresa
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4687 - 4697
12345